



**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
FIRST NAME:				
DATE OF BIRTH:				
STATE: ZIP CODE:				
PATIENT INSURANCE ID NUMBER:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI\_DISCLOSURE\_AUTHORIZATION.PDF</u>

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_

## 

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.







## Talzenna (talazoparib) Prior Authorization Request Form





MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHEI	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 📃 NO		
<b>MEDICATION/THERAPY</b> (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
<ul> <li>Metastatic breast cancer</li> <li>Locally advanced breast cancer, not amenable to curative therapy</li> <li>Other diagnosis:ICD-10</li> </ul>				
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Is the tumor positive for a deleterious or suspected deleterious germline BRCA1/2 mutation?        Yes       No     Please submit documentation				
Does the most recent tumor biopsy indicate that the tumor is HER-2 Negative?   Yes  No Please submit documentation				
Has the patient received more than three cytotoxic regimens for advanced breast cancer? <ul> <li>Yes</li> <li>No</li> </ul>				
Has the patient received treatment with an anthracycline and/or a taxane OR had a contraindication to both?				
Has the patient experienced disease progression while receiving platinum chemotherapy? $\square$ Yes $\square$ No				
Has the patient received prior treatment with another PARP inhibitor (such as olaparib/ Lynparza®, niraparib/ Zejula®, rucaparib/ Rubraca®)? □ Yes □ No				
Does the patient have leptomeningeal disease?  □ Yes □ No				
Is the patient completely ambulatory (ECOG Performance Status 0-1)?				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
*Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.				







**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

## Prescriber Signature or Electronic I.D. Verification:

Date:

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

## FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



